TGFB2 and dry eye syndrome: Gum et al. [48] demonstrated that cyclosporine A (CsA), which is increasingly used to treat moderate dry eye syndrome and ocular surface inflammation, inhibits the transformation of myofibroblasts induced by TGF-β2 in primary cultured human pterygium fibroblasts.